JP2015524816A - サラセミアを処置するためのトランスフェリンレセプターアンタゴニストの使用 - Google Patents

サラセミアを処置するためのトランスフェリンレセプターアンタゴニストの使用 Download PDF

Info

Publication number
JP2015524816A
JP2015524816A JP2015524798A JP2015524798A JP2015524816A JP 2015524816 A JP2015524816 A JP 2015524816A JP 2015524798 A JP2015524798 A JP 2015524798A JP 2015524798 A JP2015524798 A JP 2015524798A JP 2015524816 A JP2015524816 A JP 2015524816A
Authority
JP
Japan
Prior art keywords
tfr1
antibody
thalassemia
antagonist
transferrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2015524798A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015524816A5 (enExample
Inventor
クルス−モウラ，イヴァン
エルミーヌ，オリヴィエ
デュシオ，ミッシェル
プベル，エティエンヌ
トロヴァティ，マシェル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Assistance Publique Hopitaux de Paris APHP
Universite Paris Descartes
Universite Paris Diderot Paris 7
Universite Paris Sud
Fondation Imagine
Original Assignee
Centre National de la Recherche Scientifique CNRS
Assistance Publique Hopitaux de Paris APHP
Universite Paris Descartes
Universite Paris Diderot Paris 7
Universite Paris Sud
Fondation Imagine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Assistance Publique Hopitaux de Paris APHP, Universite Paris Descartes, Universite Paris Diderot Paris 7, Universite Paris Sud, Fondation Imagine filed Critical Centre National de la Recherche Scientifique CNRS
Publication of JP2015524816A publication Critical patent/JP2015524816A/ja
Publication of JP2015524816A5 publication Critical patent/JP2015524816A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015524798A 2012-08-02 2013-08-02 サラセミアを処置するためのトランスフェリンレセプターアンタゴニストの使用 Withdrawn JP2015524816A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305955.2 2012-08-02
EP12305955 2012-08-02
PCT/EP2013/066253 WO2014020140A1 (en) 2012-08-02 2013-08-02 Use of transferrin receptor antagonist for the treatment of thalassemia

Publications (2)

Publication Number Publication Date
JP2015524816A true JP2015524816A (ja) 2015-08-27
JP2015524816A5 JP2015524816A5 (enExample) 2016-09-23

Family

ID=48979730

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015524798A Withdrawn JP2015524816A (ja) 2012-08-02 2013-08-02 サラセミアを処置するためのトランスフェリンレセプターアンタゴニストの使用

Country Status (4)

Country Link
US (1) US20150197574A1 (enExample)
EP (1) EP2880059A1 (enExample)
JP (1) JP2015524816A (enExample)
WO (1) WO2014020140A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020105621A1 (ja) * 2018-11-20 2020-05-28 株式会社ペルセウスプロテオミクス 細胞内への鉄の取り込み阻害剤

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3247409B1 (en) * 2015-01-21 2020-11-04 Cornell University Viral vectors for prophylaxis and therapy of hemoglobinopathies
TWI787796B (zh) 2015-05-04 2022-12-21 美商Ｃｙｔｏｍｘ生物製藥公司 抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法
RU2737637C2 (ru) * 2015-07-22 2020-12-01 Инатерис Антитела против tfr и их применение при лечении пролиферативных и воспалительных расстройств
AU2018231127A1 (en) 2017-03-09 2019-09-19 Cytomx Therapeutics, Inc. CD147 antibodies, activatable CD147 antibodies, and methods of making and use thereof
WO2018185341A1 (en) 2017-04-07 2018-10-11 Ospedale San Raffaele S.R.L. Regulator of bmp-smad signaling and uses thereof
WO2019173771A1 (en) 2018-03-09 2019-09-12 Cytomx Therapeutics, Inc. Activatable cd147 antibodies and methods of making and use thereof
WO2021061867A1 (en) 2019-09-23 2021-04-01 Cytomx Therapeutics, Inc. Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof
WO2021195116A1 (en) * 2020-03-23 2021-09-30 The Regents Of The University Of California Transferrin receptor 1 targeting for carcinogenesis prevention
US20240100049A1 (en) * 2021-01-28 2024-03-28 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Reactivation of embryonic and fetal hemoglobin
US11939391B2 (en) * 2021-12-06 2024-03-26 MedAbome, Inc. Anti-TfR1 antibody MAb11-22.1 conjugates for cancer treatment
WO2025024334A1 (en) * 2023-07-21 2025-01-30 Marrow Therapeutics, Inc. Hematopoietic cell targeting conjugates and related methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
EP1244701A1 (en) * 1999-12-23 2002-10-02 Human Genome Sciences, Inc. Transferrin polynucleotides, polypeptides, and antibodies
US8129504B2 (en) * 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
EP1740616B1 (en) 2004-04-30 2011-12-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-tfr antibody.

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020105621A1 (ja) * 2018-11-20 2020-05-28 株式会社ペルセウスプロテオミクス 細胞内への鉄の取り込み阻害剤
JPWO2020105621A1 (ja) * 2018-11-20 2021-10-07 株式会社ペルセウスプロテオミクス 細胞内への鉄の取り込み阻害剤
JP7410051B2 (ja) 2018-11-20 2024-01-09 株式会社ペルセウスプロテオミクス 細胞内への鉄の取り込み阻害剤

Also Published As

Publication number Publication date
US20150197574A1 (en) 2015-07-16
EP2880059A1 (en) 2015-06-10
WO2014020140A1 (en) 2014-02-06

Similar Documents

Publication Publication Date Title
JP2015524816A (ja) サラセミアを処置するためのトランスフェリンレセプターアンタゴニストの使用
US10336820B2 (en) Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
US8933202B2 (en) AXL antibodies
KR102121678B1 (ko) β-KLOTHO, FGF 수용체 및 이들의 복합체에 결합하는 인간 항원 결합 단백질
EP3442578B1 (en) Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer
KR102196009B1 (ko) 항체 제형 및 방법
EP3194444B1 (en) Anti-met antibodies and compositions
WO2003016470A2 (en) Enhancing the efficacy of immunotherapies by supplementing with complement
US8992915B2 (en) Combination of CD37 antibodies with ICE
EP1957115B1 (en) Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
JP2020527552A (ja) 男性型脱毛症および女性型脱毛症用のプロラクチン受容体抗体
CN117159703B (zh) 含抗lag-3抗体的药物组合物及其用途
US20250154264A1 (en) Anti-alk1 antibodies and methods of using the same
US20230062308A1 (en) Treatment of ck8 positive cancers in relation with k-ras gene status
EP3668894A1 (en) Treatment of ck8 positive cancers in relation with k-ras gene status
TW202515906A (zh) 治療中風之方法
CN118078985A (zh) 抗tmprss6抗体及其用途
AU2013205324B2 (en) Antibodies directed to angiopoietin-1 and angiopoietin-2 and use thereof
WO2025096435A1 (en) Treatment of complement-associated renal diseases
HK40080391A (en) Use of anti-tigit antibody in the treatment of tumor or cancer
WO2024104409A1 (zh) 一种含抗rankl-ngf双特异性抗体的药物组合物
HK1259793B (zh) 用於提高血脑屏障转运的安全性的方法
HK1149023B (en) Antibodies directed to angiopoietin-1 and angiopoietin-2 and use thereof

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160729

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160729

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20161208